一名接受奥瑞珠单抗治疗的患者在接种辉瑞新冠疫苗后抗新冠病毒刺突蛋白抗体反应呈阴性 - Suppr

Suppr

超能文献

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.

作者信息

Khayat-Khoei Mahsa, Conway Sarah, Rubinson Douglas A, Jarolim Petr, Houtchens Maria K

机构信息

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

出版信息

J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.

DOI:10.1007/s00415-021-10463-3

PMID:33638680

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910800/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5538/7910800/ae626d9ed693/415_2021_10463_Fig1_HTML.jpg

相似文献

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.一名接受奥瑞珠单抗治疗的患者在接种辉瑞新冠疫苗后抗新冠病毒刺突蛋白抗体反应呈阴性

J Neurol. 2021 Oct;268(10):3592-3594. doi: 10.1007/s00415-021-10463-3. Epub 2021 Feb 27.

Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations.关于一篇论文的评论：在一名接受奥瑞珠单抗治疗的患者中，接种辉瑞新冠病毒疫苗后出现抗新冠病毒刺突蛋白抗体阴性反应——基于我们的观察对这一现象的可能解释

J Neurol. 2021 Nov;268(11):3998-3999. doi: 10.1007/s00415-021-10547-0. Epub 2021 Apr 16.

Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report.在接受奥瑞珠单抗治疗的多发性硬化症患者中，辉瑞 - 生物科技公司疫苗接种后的抗严重急性呼吸综合征冠状病毒2抗体反应：一例报告

J Int Med Res. 2021 Sep;49(9):3000605211044378. doi: 10.1177/03000605211044378.

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).肾移植受者对 BNT162b2（辉瑞-生物科技）接种 SARS-CoV-2 疫苗的体液免疫反应受损。

Viruses. 2021 Apr 25;13(5):756. doi: 10.3390/v13050756.

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者对 SARS-CoV-2 mRNA 疫苗的体液反应迟钝的初步证据。

Neurol Sci. 2021 Sep;42(9):3523-3526. doi: 10.1007/s10072-021-05397-7. Epub 2021 Jun 15.

Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study.奥瑞珠单抗治疗的多发性硬化症患者对 SARS-CoV-2 感染的抗体反应减弱：一项病例对照研究。

Mult Scler Relat Disord. 2021 Jul;52:103014. doi: 10.1016/j.msard.2021.103014. Epub 2021 May 7.

Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.针对 COVID-19 疫苗接种者和未接种者的严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）抗体：来自同一制造商的两种不同商业可用血清学检测方法的比较方法。

Clin Chim Acta. 2021 Jul;518:9-16. doi: 10.1016/j.cca.2021.03.007. Epub 2021 Mar 17.

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。

Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.

Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination.韩国健康医护人员接种辉瑞-生物科技疫苗第二剂后 1 至 2 周内的 SARS-CoV-2 抗体阳性率。

J Korean Med Sci. 2021 May 31;36(21):e158. doi: 10.3346/jkms.2021.36.e158.

The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.辉瑞 COVID-19 疫苗接种后日本国立感染症研究所-国立卫生研究所员工的保护性疫苗接种后抗体水平。

Przegl Epidemiol. 2021;75(1):3-13. doi: 10.32394/pe.75.01.

引用本文的文献

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.奥瑞珠单抗对随机 III 期 OPERA 试验中复发型多发性硬化患者 B 细胞和 T 细胞受体多样性的影响。

Neurol Neuroimmunol Neuroinflamm. 2023 Apr 24;10(4). doi: 10.1212/NXI.0000000000200118. Print 2023 Jul.

Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast.SARS-CoV-2 疫苗在短期和长期免疫中的有效性：大流行对比的综合概述。

Int J Mol Sci. 2022 Jul 30;23(15):8485. doi: 10.3390/ijms23158485.

Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.多发性硬化症患者对 SARS-CoV-2 疫苗接种的免疫反应：系统评价/荟萃分析。

Ann Clin Transl Neurol. 2022 Aug;9(8):1321-1331. doi: 10.1002/acn3.51628. Epub 2022 Jul 19.

Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets.接受克拉屈滨片治疗的多发性硬化症患者队列在完成新冠病毒疫苗接种后的体液免疫反应和淋巴细胞水平。

J Cent Nerv Syst Dis. 2021 Dec 2;13:11795735211060118. doi: 10.1177/11795735211060118. eCollection 2021.

J Int Med Res. 2021 Sep;49(9):3000605211044378. doi: 10.1177/03000605211044378.

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies.多种疾病修饰疗法治疗的多发性硬化症患者对 COVID mRNA 疫苗的体液免疫反应特征。

Vaccine. 2021 Oct 1;39(41):6111-6116. doi: 10.1016/j.vaccine.2021.08.078. Epub 2021 Sep 2.

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.多发性硬化症抗CD20疗法的分子与药理学特性的临床视角

CNS Drugs. 2021 Sep;35(9):985-997. doi: 10.1007/s40263-021-00843-8. Epub 2021 Aug 9.

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述

Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.接受克拉屈滨或奥瑞珠单抗治疗的多发性硬化症的 COVID-19 疫苗。

Mult Scler Relat Disord. 2021 Jul;52:102983. doi: 10.1016/j.msard.2021.102983. Epub 2021 May 4.

Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis.利妥昔单抗治疗多发性硬化症患者后 SARS-CoV-2 再激活。

Mult Scler Relat Disord. 2021 Jul;52:102922. doi: 10.1016/j.msard.2021.102922. Epub 2021 Mar 25.

本文引用的文献

Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.奥法妥木单抗治疗复发性多发性硬化症患者中 SARS-CoV-2 免疫球蛋白 M 和 G 抗体的产生。

Mult Scler Relat Disord. 2021 Apr;49:102777. doi: 10.1016/j.msard.2021.102777. Epub 2021 Jan 19.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。

N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.

Vaccines for COVID-19.COVID-19 疫苗。

Clin Exp Immunol. 2020 Nov;202(2):162-192. doi: 10.1111/cei.13517. Epub 2020 Oct 18.

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays Authorized for Emergency Use.四种获准紧急使用的高通量免疫分析检测 SARS-CoV-2 IgG 针对核衣壳或刺突蛋白

J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01742-20.

Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.奥瑞珠单抗对多发性硬化症患者疫苗反应的影响：VELOCE 研究。

Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.COVID-19 疫苗接种准备与自身免疫性疾病中的抗 CD20 耗竭疗法。

Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1.

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.两名接受奥瑞珠单抗治疗的多发性硬化症患者感染 COVID-19 后 SARS-CoV-2 抗体检测呈阴性。

Mult Scler Relat Disord. 2020 Sep;44:102341. doi: 10.1016/j.msard.2020.102341. Epub 2020 Jun 26.

The COVID-19 Serology Studies Workshop: Recommendations and Challenges.新型冠状病毒血清学研究研讨会：建议与挑战

Immunity. 2020 Jul 14;53(1):1-5. doi: 10.1016/j.immuni.2020.06.012. Epub 2020 Jun 23.

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.奥瑞珠单抗治疗的 MS 患者对 SARS-CoV-2 的血清学应答是否得到保留？一例报告。

Mult Scler Relat Disord. 2020 Sep;44:102323. doi: 10.1016/j.msard.2020.102323. Epub 2020 Jun 22.

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.一名使用奥瑞珠单抗且患有低丙种球蛋白血症的患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应减弱。

Mult Scler Relat Disord. 2020 Sep;44:102315. doi: 10.1016/j.msard.2020.102315. Epub 2020 Jun 20.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验